ArticlePharmaceutical research2013
RAFTsomes containing epitope-MHC-II complexes mediated CD4+ T cell activation and antigen-specific immune responses.
Article in Pharmaceutical research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 38 citations in OpenAlex.
- Engineering Functional Particles to Modulate T Cell Responses.Accounts of materials research · 2024Article
- Artificial antigen-presenting cells: the booster for the obtaining of functional adoptive cells.Cellular and molecular life sciences : CMLS · 2024Review
- Lipid-based nanoparticles for cancer immunotherapy.Medical review (2021) · 2023Review
- Progress in nanoparticle-based regulation of immune cells.Medical review (2021) · 2023Review
- Dendritic cell-mimicking scaffolds for ex vivo T cell expansion.Bioactive materials · 2023Article
- Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- Protein arginine methyltransferase 5 mediates THP-1-derived macrophage activation dependent on NF-κB in endometriosis.Experimental and therapeutic medicine · 2021Article
- Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy.Biomaterials · 2021Review
- Activation and expansion of human T cells using artificial antigen-presenting cell scaffolds.Nature protocols · 2020Article
- T cell immunotherapy enhanced by designer biomaterials.Biomaterials · 2019Review
- Engineering Platforms for T Cell Modulation.International review of cell and molecular biology · 2018Review
- The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases.Frontiers in immunology · 2018Review
- Article
- Bioengineering of Artificial Antigen Presenting Cells and Lymphoid Organs.Theranostics · 2017Review
- Degradable emulsion as vaccine adjuvant reshapes antigen-specific immunity and thereby ameliorates vaccine efficacy.Scientific reports · 2016Article
- Biomimetic and synthetic interfaces to tune immune responses.Biointerphases · 2015Review
- Engineered Materials for Cancer Immunotherapy.Nano today · 2015Article
- Cell or cell membrane-based drug delivery systems.Theranostics · 2015Review
- Liposomes as vaccine delivery systems: a review of the recent advances.Therapeutic advances in vaccines · 2014Review
- Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells.Trends in biotechnology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo develop a liposome formulation incorporating antigen-presenting cells (APCs) membrane microdomains with enriched epitope/MHC complexes to evaluate the activities of these liposomes (RAFTsomes) to activate T cells and prime immune responses.
methodsWe isolated membrane microdomain structures that contained the epitope/MHC complexes from ovalbumin (OVA) primed dendritic cells (DCs), and reconstituted them on liposomes surface by detergent dialysis. The resulted RAFTsomes were purified by density gradient centrifugation. Their T cell activation functions were evaluated by IL-2 secreting and proliferation assays in vitro. In vivo immune responses and the protective effect against OVA expressing EG.7 tumor challenge were also examined.
resultsMembrane microdomains containing enriched epitope/MHC complexes can be reconstituted into liposomes with defined size and composition. The integrity and activities of these complexes after reconstitution were confirmed by in vitro T cell assays. OVA epitope loaded RAFTsomes injected in vivo resulted in high anti-OVA IgG production (predominantly IgG1). The immunized mice were protected from EG.7 tumor cell inoculation challenge.
conclusionsBased on these findings, we propose that RAFTsomes can be prepared with unique properties that may be used as an antigen delivery system for immunotherapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.